Real-World Application of Subcutaneous Efgartigimod in Chronic Inflammatory Demyelinating Polyradiculoneuropathy

This case series reports the real-world outcomes of subcutaneous efgartigimod in four patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Among the three typical CIDP cases, one showed a marked improvement, whereas two showed only a limited benefit and discontinued treatment. Another patient diagnosed with motor CIDP (motor-predominant CIDP) experienced a sustained improvement. Favorable responders tended to exhibit motor-dominant symptoms. No serious adverse events occurred, although one patient reported mild post-injection fatigue. These findings suggest that the clinical response to efgartigimod varies even within typical CIDP, likely due to underlying disease heterogeneity, thereby underscoring the need for larger studies to identify the predictors of treatment responsiveness.